Source: Taiwantrade | Updated: 06 November 2012
The center will focus on drugs for geriatric chronic disease and infectious diseases such as Severe Acute Respiratory Syndrome, which usually breaks out in urban areas in Asia, as well as skin cancer.
There will also be further studies on diseases that affect only a small percentage of the world population, such as Fabry disease, GSK said.
The drug maker said the partnership will allow it to use Asian patients for testing its products, which have been well-tested on humans of other ethnicities.
While the GSK has been working with various local hospitals to conduct clinical trials, its collaboration with Chang Gung will contribute to more consistent tests, said James Shannon, GSK's chief medical officer.